Clinical observation on treatment of diabetic nephropathy by tangweikang capsule

Lan Lin; Qing Ni; Qi-Jian Gao; Run-Yun Zhang; Dong-Peng Hu; Xi-Ming Liu; Cheng-Lian Su; Si-Lan Chen; Jun-Ping Wei; Ming-Di Li

doi:10.1007/BF02934612

Your Location：

Home >

Browse articles >

Clinical observation on treatment of diabetic nephropathy by tangweikang capsule

Updated：2021-08-27

- Clinical observation on treatment of diabetic nephropathy by tangweikang capsule
- Chinese Journal of Integrative Medicine Vol. 8, Issue 1, Pages: 19-23(2002)
- Affiliations：
  
  Guang‘anmen Hospital, China Academy of TCM,Beijing
- Author bio：
- Funds：
  
  The study belonged, to State “Nine-Five” Key Projects (No. 96-906-07)
- DOI：10.1007/BF02934612
  CLC：
- Published：2002，
Scan for full text
Lin, L., Ni, Q., Gao, QJ. et al. Clinical observation on treatment of diabetic nephropathy by tangweikang capsule., CJIM 8, 19–23 (2002). https://doi.org/10.1007/BF02934612

Lan Lin, Qing Ni, Qi-Jian Gao, et al. Clinical observation on treatment of diabetic nephropathy by tangweikang capsule. [J]. Chinese Journal of Integrative Medicine 8(1):19-23(2002)
Lin, L., Ni, Q., Gao, QJ. et al. Clinical observation on treatment of diabetic nephropathy by tangweikang capsule., CJIM 8, 19–23 (2002). https://doi.org/10.1007/BF02934612 DOI：

Lan Lin, Qing Ni, Qi-Jian Gao, et al. Clinical observation on treatment of diabetic nephropathy by tangweikang capsule. [J]. Chinese Journal of Integrative Medicine 8(1):19-23(2002) DOI： 10.1007/BF02934612.

摘要

To observe the effect of Tangweikang Capsule

(TWK) on diabetic nephropathy (DN). The 119 DN patients were divided into two groups: the group of TWK treatment (n=78) and group of captopril (n=41) as the control

the dose of which was 50 mg/d. The treatment lasted for 12 weeks. The changes of symptom score

urinary microprotein series

blood glucose

renal function

etc. were observed. The total effective rate of the TWK group was 84.62% ; and that of the control group. was 70.73%

there was significant difference between the two groups (P<0.05). TWK treatment reduced the levels of blood glucose

blood lipid

serum creatinine

blood urea nitrogen

albumin

β -microglobulin and Tamm-Horsfall protein (P<0.05

P<0.01) in DN patients. The levels of triglyceride

angiotensin I

angiotensin II

atrial natriuretic polypeptide

prostaglandins

endothelin

type IV collagen and total cholesterol decreased and the level of high density lipoprotein-cholesterol increased in the serum of TWK-treated DN patients (P<0.05

P<0.01). TWK exerted obviously ameliorating effect on renal function in DN patients.

Abstract

To observe the effect of Tangweikang Capsule

(TWK) on diabetic nephropathy (DN). The 119 DN patients were divided into two groups: the group of TWK treatment (n=78) and group of captopril (n=41) as the control

the dose of which was 50 mg/d. The treatment lasted for 12 weeks. The changes of symptom score

urinary microprotein series

blood glucose

renal function

etc. were observed. The total effective rate of the TWK group was 84.62% ; and that of the control group. was 70.73%

there was significant difference between the two groups (P<0.05). TWK treatment reduced the levels of blood glucose

blood lipid

serum creatinine

blood urea nitrogen

albumin

β -microglobulin and Tamm-Horsfall protein (P<0.05

P<0.01) in DN patients. The levels of triglyceride

angiotensin I

angiotensin II

atrial natriuretic polypeptide

prostaglandins

endothelin

type IV collagen and total cholesterol decreased and the level of high density lipoprotein-cholesterol increased in the serum of TWK-treated DN patients (P<0.05

P<0.01). TWK exerted obviously ameliorating effect on renal function in DN patients.

关键词

Tangweikang capsulediabetic nephropathyRenal Function

Keywords

Tangweikang capsulediabetic nephropathyRenal Function

references

Wang Hy. Nephrology. 2nd edition. People’s Health Publishing House, 1996: 959-967.

Mogensen CE. Management of early nephrology in diabetic patients. Ann Rev Med 1995; (46):79.

Syndrome differentiation, diagnosis and efficacy assessment standard. Shaanxi TCM 1988 ; (1):3rd page of inside cover.

Ministry of Health. Guideline of clinical study on Chinese new drug in treating diabetes mellitus. 1987: 215-218.

Ministry of Health. Guideline of clinical study on Chinese new drug in treating chronic glomerulonephritis. 1992:97.

Lin L. Integrated traditional and western medicine diabetol- ogy. Beijing: Chinese Medical Science & Technoloy Press, 1999:394–409.

Yin J, Guo Lg. Modern research and clinical application of Chinese drugs. Beijing: Xueyuan Press, 1993:815,676, 1036.

Wang Xw. Progress in diagnosis and treatment of diabetic nephropathy. Chin Practical J Internal Med 1995; 15 (6): 361.

Liu Jf, Wen Jk. Progress in study of endothelin and renal function. Foreign Med, Physiology, Pathology and Clinical Fascicle 1997; 17(2): 145.

FULL TEXT LINK

More>

Views

349

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Total triterpene acids, isolated from Corni Fructus, ameliorate progression of renal damage in streptozotocin-induced diabetic rats

Study on the relationship between chinese medicine constitutive susceptibility and diversity of syndrome in diabetic nephropathy

Regulation of C-type natriuretic peptides and natriuretic peptide receptor-B expression in diabetic rats renal treated by Tongluo Recipe (通络方)

Association of Chinese medicine constitution susceptibility to diabetic nephropathy and transforming growth factor-β1 (T869C) gene polymorphism

Effects of panax notoginoside on the nephropathy in rats with type 1 diabetes mellitus

Related Author

No data

Related Institution

Department of Pharmacy, College of Chemical and Chemistry Engineering, Hu’nan University

Department of Basic Guiyang College of Traditional Chinese Medicine

Department of Pharmacology, College of Pharmaceutical Sciences, Zhejiang University of Technology

Zhejiang University of Traditional Chinese Medicine

Dongzhimen Hospital, Beijing University of Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰